Clinical Trial Update: A Study of Galunisertib on the Immune System in Participants With Cancer [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating Galunisertib's effects on the immune system in cancer patients. The study is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Galunisertib (galunisertib)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Neoplasm | Phase 1 | Status: COMPLETED